Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


An Erratum to this article was published on 01 February 2011

This article has been updated


In September 2010, pegloticase (Krystexxa; Savient Pharmaceuticals), a recombinant urate oxidase conjugated to polyethylene glycol (PEG), was approved by the US Food and Drug Administration (FDA) for the treatment of chronic gout in adult patients refractory to conventional therapy.

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Pathogenesis of gout and targets for therapeutic intervention.

Change history

  • 18 January 2011

    Naomi Schlesinger is affiliated with the Robert Wood Johnson Medical School, New Jersey, USA, not the University Hospital, as stated. This has been corrected in the online version.


  1. 1

    Richette, P. & Bardin, T. Gout. Lancet 375, 318–328 (2010).

    CAS  Article  Google Scholar 

  2. 2

    Palmer, D. G., Highton, J. & Hessian, P. A. Development of the gout tophus. An hypothesis. Am. J. Clin. Pathol. 91, 190–195 (1989).

    CAS  Article  Google Scholar 

  3. 3

    Burns, C. M. & Wortmann, R. L. Gout therapeutics: new drugs for an old disease. Lancet 16 Aug 2010 (doi:10.1016/S0140-6736(10)60665-4).

    CAS  Article  Google Scholar 

  4. 4

    Zhang, W. et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann. Rheum. Dis. 65, 1312–1324 (2006).

    CAS  Article  Google Scholar 

  5. 5

    Pascual, E. et al. Febuxostat. Nature Rev. Drug Discov. 8, 191–192 (2008).

    Article  Google Scholar 

  6. 6

    Sundy, J. S. et al. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum. 56, 1021–1028 (2007).

    CAS  Article  Google Scholar 

  7. 7

    Sundy, J. S. et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum. 58, 2882–2891 (2008).

    Article  Google Scholar 

  8. 8

    US Food and Drug Administration. FDA labelling information — Krystexxa (pegloticase). FDA website [online], (2010).

  9. 9

    Thiele, R. G. & Schlesinger, N. Ultrasonography shows active inflammation in clinically unaffected joints in chronic tophaceous gout. Arthritis Rheum. 60, S565 (2009).

    Google Scholar 

  10. 10

    Mandel, D. R. et al. Use of pegloticase in chronic gout refractory to conventional therapy is associated with significant clinical benefit: tender joint and swollen joint counts and patient global assessment (Health Assessment Questionnaire). Arthritis Rheum. 62, S166 (2010).

    Google Scholar 

  11. 11

    Schlesinger, N. et al. Efficacy of canakinumab (ACZ885), a fully human anti-interleukin (IL)-1beta monoclonal antibody, in the prevention of flares in gout patients initiating allopurinol therapy. Arthritis Rheum. 62, S2087 (2010)

    Google Scholar 

  12. 12

    Terkeltaub, R. et al. Evaluation of rilonacept for prevention of gout flares during initiation of urate-lowering therapy: results of a phase 3, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 62, S152 (2010).

    Google Scholar 

  13. 13

    Baert, F. et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348, 601–608 (2003).

    CAS  Article  Google Scholar 

  14. 14

    IMS MIDAS (2010).

  15. 15

    Richter, S. & Ekas, L. Collins Stewart Report on Savient Pharmaceuticals. (Collins Stewart, 5 Nov 2010),

    Google Scholar 

  16. 16

    Werher, C. Summer Street Report on Savient Pharmaceuticals. (Summer Street, 8 Nov 2010).

    Google Scholar 

Download references


U.Y. would like to thank D. Hanicq for assistance in data collection.

Author information



Ethics declarations

Competing interests

Naomi Schlesinger has acted as a consultant for and received grants from Novartis, has been part of the speakers bureau for Takeda, and has participated in advisory boards for novartis, Takeda, URL Pharma, Savient and RX Enzyme.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Schlesinger, N., Yasothan, U. & Kirkpatrick, P. Pegloticase. Nat Rev Drug Discov 10, 17–18 (2011).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing